Intelligence / BPC-157

BPC-157

Prescription Only
Tissue Repair
Schedule
S4
Prescription Only
Enforcement
Stable
Low Risk
Providers
18
Access: Clear
Key Facts
Schedule 4 - Prescription Only
15 amino acid synthetic peptide
18 identified Australian providers
Stable regulatory environment
Widely compounded in Australia

Overview

BPC-157 is a synthetic peptide consisting of 15 amino acids, derived from a protein found in human gastric juice. It is one of the most widely prescribed peptides in Australia, available through compounding pharmacies with a valid prescription.

Australian Scheduling

Classified as Schedule 4 (Prescription Only) under the Poisons Standard. Requires a valid prescription from an AHPRA-registered medical practitioner. No anticipated scheduling changes for 2026-2027.

Access Pathway

Available through most telehealth peptide clinics and compounding pharmacies nationally. This is one of the most accessible prescription peptides in the Australian market, with 18 identified providers offering consultations.

Regulatory Notice

For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.

News & Updates20 items
Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation.
Integrative medicine (Encinitas, Calif.)1 June 2026
Protective effects of BPC 157 in rats with experimentally induced lower extremity deep vein thrombosis
J Integr Neurosci28 May 2026
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Pharmacokinetics, and Clinical Translation
Adv Drug Deliv Rev20 May 2026
Peptide craze sparks Lancet warning
Medical Republic12 May 2026
The peptide problem: hype is outrunning the evidence
The Conversation6 May 2026
TGA warning on the risks of importing unapproved peptide products
TGA6 May 2026
Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery
J Clin Med2 May 2026
Grey-market peptides an emerging public health challenge
MJA InSight+28 Apr 2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
International journal of molecular sciences27 Apr 2026
FDA to hold July 2026 meeting on easing restrictions on BPC-157, TB-500 and other peptides
Business Insider25 Apr 2026
FDA to weigh easing limits on unproven peptides favored by RFK Jr.
AP News15 Apr 2026
TGA warns suppliers: importing and compounding unapproved peptides is illegal
AJP13 Apr 2026
Understanding your responsibilities when importing, compounding and supplying unapproved peptide products
TGA12 Apr 2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Sports medicine (Auckland, N.Z.)12 Apr 2026
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
Frontiers in aging7 Apr 2026
Patient would rather take BPC-157 than a statin — revealing an uncomfortable truth in medicine
Stat News3 Apr 2026
BPC-157 human clinical trials status 2025-2026: 3 published studies, 1 cancelled Phase I, FDA Category 2
Peptide Database1 Apr 2026
BPC-157 not currently captured in the Poisons Standard — interim decisions ACMS #43 ACCS #37
TGA1 Apr 2026
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — 36 preclinical, 1 clinical study
SAGE Journals1 Apr 2026
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study — no adverse effects, well-tolerated
PubMed1 Apr 2026

Are You a Practitioner?

List your clinic for free and reach patients actively searching for legal peptide access in Australia.